Complain about a product or service

FDA Wants Stronger Anti-Depressant Warnings

May 3, 2007

Depression • Study Probes Link Between Antidepressants, Birth Defects • Antidepressant Use Increasing In The United States • Children May Be Impacted By Parents' Anxiety Disorder • Higher Rx Costs May Limit Seniors’ Access to Antidepressants • Dual Approach Best for Depressed Teens • Depression Not a Normal Part of Aging • Study: Few Risks from Antidepressant Use During Pregnancy • Panel Finds Omega 3 Little Help Against Depression • Antidepressants Similar in Effectiveness, But Side Effects Differ • Antidepressants: Crutch or Catalyst? • Drugs Not Always a Cure for Depression Dr. Henry Fishman: • Don't Give Up On Depression • Exercise and Depression • The Winter Blues --- • First-Time Mothers at Increased Risk for Depression • Holidays May Bring Out Depression In Seniors • Depression Bigger Problem For Men Than Women • FDA Approves the First Drug for Seasonal Depression • Acne Drug's Possible Depression Link Under Review • Treating Depression May Mean Trying Different Drugs • Study Suggests Antidepressant-Suicide Link • FDA OKs Patch For Depression • Feeling the Holiday Blues? You Must Have Children • Gene May Trigger Depression, Study Finds • Exercise and Depression • Former Prozac Users Slam FDA • Consumer Drug Ads May Influence Doctors' Rx Decisions

The U.S. Food and Drug Administration is asking the makers of all antidepressant medications update the existing black box warning on their products' labeling to include warnings about increased risks of suicidal thinking and behavior, known as suicidality, in young adults ages 18 to 24 during initial treatment.

The proposed labeling changes also include language stating that scientific data did not show this increased risk in adults older than 24, and that adults ages 65 and older taking antidepressants have a decreased risk of suicidality.

The proposed warning statements emphasize that depression and certain other serious psychiatric disorders are themselves the most important causes of suicide.

"Depression and other psychiatric disorders can have significant consequences if not appropriately treated. Antidepressant medications benefit many patients, but it is important that doctors and patients are aware of the risks," said Steven Galson, M.D., MPH, director of FDA's Center for Drug Evaluation and Research.

People currently prescribed antidepressant medications should not stop taking them, the agency said. Those who have concerns should notify their health care providers.

The proposed labeling changes apply to the entire category of antidepressants.

Results of individual placebo-controlled scientific studies are reasonably consistent in showing a slight increase in suicidality for patients taking antidepressants in early treatment for most of the medications.

Available data are not sufficient to exclude any single medication from the increased risk of suicidality

The proposed labeling update follows similar labeling changes made in 2005 that warned of a suicidality risk in children and adolescents who use antidepressants. At that time, FDA asked manufacturers to add a black box warning to the labeling of all antidepressants to describe this risk and to emphasize the need for appropriate monitoring and close observation, particularly for younger patients taking these medications.

In addition, FDA directed manufacturers to develop Medication Guides, FDA-approved user-friendly information for patients, families and caregivers, that could help improve monitoring. Medication Guides are intended to be distributed at the pharmacy with each prescription or refill of a medication.

Also in 2005, FDA began a comprehensive review of 295 individual antidepressant trials that included over 77,000 adult patients with major depressive disorder (MDD) and other psychiatric disorders, to examine the risk of suicidality in adults who are prescribed antidepressants.

In December 2006, FDA's Psychopharmacologic Drugs Advisory Committee agreed that labeling changes were needed to inform health care professionals about the increased risk of suicidality in younger adults using antidepressants.

Additionally, the committee noted product labeling needed to reflect the apparent beneficial effect of antidepressants in older adults and to remind health care professionals that the disorders themselves are the most important cause of suicidality.

FDA has been developing language to revise product labeling and update the Patient Medication Guides for these products. Manufacturers of antidepressants will now have 30 days to submit their revised product labels and revised Medication Guides to FDA for review.

Products involved in the latest action include: Anafranil (clomipramine)
Asendin (amoxapine)
Aventyl (nortriptyline)
Celexa (citalopram hydrobromide)
Cymbalta (duloxetine)
Desyrel (trazodone HCl)
Elavil (amitriptyline)
Effexor (venlafaxine HCl)
Emsam (selegiline)
Etrafon (perphenazine/amitriptyline)
fluvoxamine maleate Lexapro (escitalopram hydrobromide)
Limbitrol (chlordiazepoxide/amitriptyline)
Ludiomil (maprotiline)
Marplan (isocarboxazid)
Nardil (phenelzine sulfate)
nefazodone HCl Norpramin (desipramine HCl)
Pamelor (nortriptyline)
Parnate (tranylcypromine sulfate)
Paxil (paroxetine HCl)
Pexeva (paroxetine mesylate)
Prozac (fluoxetine HCl)
Remeron (mirtazapine)
Sarafem (fluoxetine HCl)
Seroquel (quetiapine)
Sinequan (doxepin)
Surmontil (trimipramine)
Symbyax (olanzapine/fluoxetine)
Tofranil (imipramine)
Tofranil-PM (imipramine pamoate)
Triavil (perphenazine/amitriptyline)
Vivactil (protriptyline)
Wellbutrin (bupropion HCl)
Zoloft (sertraline HCl)
Zyban (bupropion HCl)

Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.

Share		Follow us on Twitter.